Cognition Therapeutics to Host Third Quarter 2026 Financial Results and Business Update Call on November 5, 2026
Key Highlights
- ➤Cognition Therapeutics (CGTX) will report Q3 2026 financial results November 5
- ➤Conference call and webcast scheduled for 8:30 a.m. ET November 5
- ➤Lead candidate zervimesine (CT1812) demonstrated promise in Phase 2 trials
- ➤Company has received nearly $200 million in NIH and foundation grants
PURCHASE, N.Y., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders (the “Company” or “Cognition”), today announced that the Company will host a conference call and webcast on November 5, 2026, at 8:30 a.m. Eastern Time to report its financial results for the third quarter ended September 30, 2026, and provide a business update.
Conference Call & Webcast Details Title: Cognition Third Quarter 2026 Financial Results and Business Update Date: November 5, 2026 Time: 8:30 a.m. Eastern Time Dial In: Toll Free (US & Canada) 1-800-715-9871 US/International Toll: 1-646-307-1963 Conference ID: 9023814 Call me™: https://registrations.events/easyconnect/9023814/recFvJxj663evg74H/ Webcast: https://webcast.ir-events.com/bKXwO501v80
Get started
Create a free account to read the full story.